A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
← catalyst calendarNCT05776472 · readout in 1,092 d
Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With IQVIA Pty Ltd.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
87
Countries
Australia, Belgium, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-26 | actual | When the study began enrolling |
| Primary completion | 2029-08-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-21 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Nocturnal Hemoglobinuria
Intervention
- Drug: Pegcetacoplan — also filed as Aspaveli, Empaveli
Primary outcome
what the primary-completion date above is the date OFChange in observed hemoglobin level from initiation of treatment with pegcetacoplan to 6 months
measured 6 months
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed